Market Overview

Johnson & Johnson Completes Divestiture Of Ortho-Clinical Diagnostics To The Carlyle Group For $4B

Share:
Related JNJ
Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow
How Family Office Manager Julio Gonzalez Is Helping Keep Jobs In The U.S. Using Tax Engineering
The Vetr community has upgraded $JNJ to 3.5-Stars. (Vetr)

Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9 billion in 2013.

Johnson & Johnson will discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.

Posted-In: News Health Care Legal Press Releases General

 

Related Articles (JNJ)

View Comments and Join the Discussion!